Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Takeda Obtains 100% Control of China JV

publication date: Oct 21, 2010
Takeda Pharma of Japan will acquire the remaining 25% of its China JV, Tianjin Takeda Pharmaceuticals Co., Ltd., from its former partner, Tianjin Lisheng Pharma, giving Takeda complete control of the enterprise. Lishing, a state-owned company, decided last year to sell its 25% stake. By law, Lishing was required to hold an auction, and Takeda was the only bidder, though the amount was not disclosed. More details....

Stock Symbol: (TO: 4502)


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here